The exclusive, first-hand, behind-the-scenes story of how Pfizer raced to create the first Covid-19 vaccine, told by Pfizer's CEO Dr. Albert Bourla A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made "the impossible possible"--creating, testing, and manufacturing a safe and effective Covid-19 vaccine that previously would have taken years to develop. Dr. Bourla chronicles how the brilliant, dedicated minds at Pfizer, under the enormous strains of the global pandemic, overcame a series of crises that were compounded by social and political unrest, and reveals the doubts, decisions, obstacles, and failures they encountered. As Dr. Bourla makes clear, Pfizer's success wasn't due to luck; it was because of preparation driven by four simple values--Courage, Excellence, Equity, and Joy. Moonshot is a story of leadership under the most unprecedented circumstances--how Dr. Bourla, a Greek immigrant, a child of Holocaust survivors, and a veterinarian, became the head of one of the world's largest corporations and initiated a dramatic transformation of the organization just before a global health crisis would serve to test the organization, its scientists and its leader, like never before. Moonshot describes best practices that can be used to address the multiple, unprecedented challenges our world faces, reveals Pfizer's implementation of scientific breakthroughs at a record-breaking pace, and offers leadership lessons that can help anyone successfully manage their own seemingly unsolvable problems. As Dr. Bourla explains, "I am sharing the story of our moonshot--the challenges we faced, the lessons we learned, and the core values that allowed us to make it happen--in hopes that it might inspire and inform your own moonshot, whatever that may be."

"A collection of diverse viewpoints from over 45 thought leaders in the biotechnology industry and their efforts going forward during the COVID-19 pandemic. Biotechnology in the Time of COVID-19 is the opening chapter of a story of how the biotechnology industry rose to battle the COVID-19 virus-told by the leaders of that industry in their own words. The industry has built over more than forty years, an ecosystem of scientists, entrepreneurs, doctors, investors, venture capitalists, analysts, media, and bankers, all committed to advancing global health. In two months, leaders and companies from this ecosystem pivoted from the work they were carrying on pre-COVID-19 to face the virus. Forty-six seven contributors offer historical, personal, and investor perspectives, views from inside the biotech companies, broad lessons, leadership, and a look to the future. COVID-19 was a crisis anticipated by many, but one for which we were inadequately prepared. That has led to an unnecessary catastrophe. Now is the time to shine a light on those who bring hope that we will push back the virus with science and medicine. This book is a collection of the voices from the front of that fight. All share the commitment to fight and the conviction that science and medicine will prevail. The editor royalties and a portion of publisher revenues will be donated to two nonprofits focused on rare disease research: Global Genes (globalgenes.org) and The Institute for Life Changing Medicines (lifechangingmedicines.org)"--

This work has been selected by scholars as being culturally important, and is part of the knowledge base of civilization as we know it. This work is in the "public domain in the United States of America, and possibly other nations. Within the United States, you may freely copy and distribute this work, as no entity (individual or corporate) has a copyright on the body of the work. Scholars believe, and we concur, that this work is important enough to be preserved, reproduced, and made generally available to the public. We appreciate your support of the preservation process, and thank you for being an important part of keeping this knowledge alive and relevant.

Biotechnology (BT) offers exciting and promising prospects for healing the sick and relieving the suffering. But because of their impressive powers to alter the workings of body and mind, the "dual uses" of the same technologies make them attractive also to people who are not sick but who would use them to look younger, perform better, feel happier, or become more "perfect." These applications of BT present us with difficult challenges. This report considers such possible "beyond therapy" uses and explores both their scientific basis and the ethical and social issues they will raise. In enjoying the benefits of BT, we will need to hold fast to an account of the human being, seen not in material or mechanistic or med. terms, but in psychic and moral and spiritual ones.

One of the most impassioned debates to have recently gripped Australian politicians and the public at large has been about the use of embryonic stem cells in medical research. This book examines all the issues.